WATSON 3209 (Rivastigmine 3 mg)
Pill imprint WATSON 3209 has been identified as Rivastigmine tartrate 3 mg.
Rivastigmine is used in the treatment of alzheimer's disease; parkinson's disease; lewy body dementia and belongs to the drug class cholinesterase inhibitors. There is no proven risk in humans during pregnancy. Rivastigmine 3 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Imprint:
- WATSON 3209
- Strength:
- 3 mg
- Color:
- Yellow
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Cholinesterase inhibitors
- Pregnancy Category:
- B - No proven risk in humans
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Watson Pharmaceuticals
- National Drug Code (NDC):
- 00591-3209
- Inactive Ingredients:
- silicon dioxide colloidal
hypromellose
magnesium stearate
microcrystalline cellulose
gelatin
titanium dioxide
ferric oxide yellow
| NDC Code | Manufacturer / Repackager |
|---|---|
| 63739-0577 | McKesson Packaging Services |
Note: Inactive ingredients may vary.
More about rivastigmine
Consumer resources
- Rivastigmine
- Rivastigmine patch
- Rivastigmine solution
- Rivastigmine transdermal
- Rivastigmine (Advanced Reading)
- Rivastigmine Transdermal (Advanced Reading)
- Other brands: Exelon
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
